カルシヌーリンの発現,活性化,および心臓の圧力過負荷性多動症における機能
H W Lim1, L J De Windt, L Steinberg
1Department of Pediatrics, Children's Hospital Medical Center, University of Cincinnati, Ohio, USA.
Circulation
|May 24, 2000
まとめ
カルシーヌーリンの活性度は心臓の負荷とともに増加し,心臓の縮に寄与する. シクロスポリンA (CsA) でカルシネウリンを阻害すると,ネズミのこの高縮症は弱まり,部分的に逆転した.
科学分野:
- 心血管生物学 心血管生物学
- 分子心臓病学 分子心臓病学
- 生理学 生理学とは
背景:
- 血管高血圧は心臓の負荷を増加させ,左心室の縮と心臓病を引き起こす.
- 心筋縮を調節する分子経路は完全に理解されていません.
- カルシヌーリンは,カルシウムに敏感なフォスファターゼであり,心臓高縮の潜在的調節因子である.
研究 の 目的:
- 圧力過負荷によって引き起こされる心筋縮におけるカルシヌーリンの役割を調査する.
- カルシーヌーリンの活動と発現が心臓の負荷とともに増加するかどうかを判断する.
- カルシヌーリンの阻害が心筋縮に及ぼす効果を評価する.
主な方法:
- ネズミでは,腹部大動脈帯状帯状による圧力過負荷誘発性高縮症.
- 心臓組織におけるカルシーヌーリンの酵素活性とタンパク質含有量を測定した.
- カルシヌーリンとカルモドゥリンの関連性を評価するために,ウエスタン・ブロット分析を用いた.
- カルシヌーリンの阻害剤であるサイクロスポリンA (CsA) をネズミに投与した.
主要な成果:
- カルシヌーリンの酵素活性とタンパク質含有量は,圧力過負荷高縮への反応として有意に増加した.
- カルシネウリンタンパク質の含有量の増加は,カルモジュリン結合の増加と関連していました.
- CsAの投与は,投与量に依存した方法で心筋縮を予防し,部分的に逆転させました.
- CsA治療は,縮症の組織学的および分子的マーカーを弱めた.
結論:
- カルシヌーリンは,負荷誘発性心筋縮の主要な上流調節剤である.
- CsAによるカルシヌーリンの抑制は,心筋縮の管理のための潜在的な治療戦略を提供します.
関連する概念動画
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...


